Novartis: EC approves Enerzair Breezhaler for asthma

(CercleFinance.com) - Swiss drugmaker Novartis's Enerzair Breezhaler has received European Commission approval for the treatment of uncontrolled asthma.


The Commission has approved the device as a maintenance treatment of asthma in adult patients who are not adequately controlled with a maintenance combination of a long‑acting beta2‑agonist and a high-dose of an inhaled corticosteroid who have experienced one or more asthma exacerbations in the previous year, the group said on Tuesday.

The approval also includes an optional digital companion with sensor and app that provides inhalation confirmation, medication reminders and access to data.

Copyright (c) 2020 CercleFinance.com. All rights reserved.